Category: Patently BIOtech
Seventy Nine House Members Express Concern with H.R. 9
House leaders made the decision earlier this month to remove patent reform legislation from the …
CNBC Commentary: Hedge funds, 'reverse trolls' crushing biopharma innovation
Patents are the lifeblood of medical innovation. They are the cornerstone that enables companies to …
Understanding the Wider Implications of HR 9: Patent Reform's Impact on Agriculture
The House Judiciary Committee recently approved H.R. 9, the Innovation Act, legislation they hoped would …
IP Sessions at BIO 2015: The Evolving Landscape of Patentable Subject Matter
The IP Track at BIO 2015 had a number of incredible educational sessions concerning the …
This Independence Day, Let’s Thank the Inventors
Happy Birthday AMERICA! That’s right, this Saturday is July 4. And yes, that means what …
IP Sessions at BIO 2015: The Impact of the Inter Partes Review on (BIO)Pharma
The Intellectual Property Track at the BIO International Convention was a chance for IP thought …
FDA Acts on Biosimilars
The Biologics Price Competition and Innovation Act (BPCIA) deferred to the Food and Drug Administration …
Biosimilars at the Federal Circuit – Can the Parties Be Compelled to Dance?
In 2009, Congress passed the Biologics Price Competition and Innovation Act (“BPCIA”), which for the first …
11 Days Until BIO 2015: IP Networking and Meetup Opportunities
This year’s BIO International Convention is fast approaching, with plenty of opportunities for the best …
IP Sessions at the 2015 BIO International Convention
This year’s BIO International Convention will be host to educational sessions on the latest issues …